title: Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening.
abstract: With the introduction of mammographic screening the incidence of ductal carcinoma in situ (DCIS) has increased to 10-15% of all breast cancers. The aim of this study was to investigate whether there were any morphological and cell biological differences between DCIS detected during the pre-screening (n = 39) as opposed to the screening period (n = 120). We could not demonstrate any statistically significant differences between the pre-screening and the screening period with regard to nuclear grade, presence of necrosis, the Van Nuys classification system, growth pattern, or cell biological factors (estrogen and progesterone receptors, c-erbB-2, p53, DNA ploidy status, Ki67, and Auer classes). These findings suggest that DCIS tumors detected during the two time periods have a similar malignant potential. DCIS detected during the screening period was further divided into the prevalence period versus the period thereafter, and symptomatic versus screening-detected asymptomatic cases. More cases with diffuse growth patterns were seen during the prevalence period than after the prevalence period, and screening-detected asymptomatic DCISs were more often 15 mm or smaller in diameter than DCISs detected symptomatically.
authors.affiliation: Department of Pathology/Cytology, University Hospital, Lund, Sweden.
authors.forename: I
authors.initials: I
authors.lastname: Idvall
authors.forename: C
authors.initials: C
authors.lastname: Andersson
authors.forename: G
authors.initials: G
authors.lastname: Fallenius
authors.forename: C
authors.initials: C
authors.lastname: Ingvar
authors.forename: A
authors.initials: A
authors.lastname: Ringberg
authors.forename: C
authors.initials: C
authors.lastname: Strand
authors.forename: M
authors.initials: M
authors.lastname: Akerman
authors.forename: M
authors.initials: M
authors.lastname: Fernö
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000473:pathology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000737:chemistry / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000473:pathology*; D002467:Cell Nucleus / Q000648:ultrastructure; D005260:Female; D006801:Humans; D015994:Incidence; D019394:Ki-67 Antigen / Q000032:analysis; D008327:Mammography; D008403:Mass Screening; D009336:Necrosis; D009363:Neoplasm Proteins / Q000032:analysis*; D011003:Ploidies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53